Phosphate
|
Basic information |
| Metabolite name | Phosphate |
 | HMDB0001429 |
 |
C00009 |
 |
1004 |
| Synonyms | Hydrogen phosphate |
| No. of studies | 18 |
|
Basic information |
| Metabolite name | Phosphate |
| HMDB0001429 |
|
C00009 |
|
1004 |
| Synonyms | Hydrogen phosphate |
| No. of studies | 18 |
|
Relationship between Phosphate and depression (count: 18) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M348 | Type1 | depression group vs. control group | Gray matter | Human | Down |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M543 | Type1 | summer depression group vs. summer control group | Plasma | Human | Up |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Up |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M971 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |